Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development

This study includes 2 phases. During phase 1, pregnant women are followed over the course of pregnancy. The phase 2 is a follow-up of the mother-child dyad at 3, 5 and 10-12 year after delivery.

The purpose of this phase 1 is to :

* assess the contribution and interactions of adipokines in the development of insulin resistance during pregnancy and gestational diabetes; * assess levels of maternal adipokines as determinants of development and fetal growth; * determine the genetic variations that influence levels of adipokines and glucose regulation during pregnancy and in newborns.

The purpose of this phase 2 is to:

* identify DNA methylation variations at birth that are predictive of childhood overweight/obesity. * identify maternal characteristics associated with DNA methylation variations predictive of childhood overweight/obesity. * establish whether the loci predictive of childhood overweight/obesity at birth are still differentially methylated at 5 years of age (samples collected at 5 years of age). * identify DNA methylation variations at birth that are predictive of childhood neurodevelopment problems at 3, 5 and 10 years of age.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Gestational Diabetes Body Weight Diabetes Mellitus Diabetes, Gestational Endocrine System Diseases Female Urogenital Diseases and Pregnancy Complications Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Obesity Prevention Overnutrition Overweight Pathological Conditions, Signs and Symptoms Pregnancy Complications Signs and Symptoms Urogenital Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Sherbrooke, Quebec, J1H5N4, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

age ≥ 18 yrs
gestational age between 6 and 13 weeks from last menstrual period
no recognized diabetes or drugs interfering with glucose metabolism
alcohol < 2 drinks/day
not involved in regular high intensity physical activity
otherwise good health status

Exclusion criteria

twin pregnancy

Treatment and study plan

Primary outcomes

Diagnosis of gestational diabetes mellitus

Time frame: 24-28 weeks of gestation

75g oral glucose tolerance test

Sponsors and collaborators

Lead sponsor

Université de Sherbrooke

Other

Collaborators

American Diabetes Association
Canadian Institutes of Health Research (CIHR)
Diabetes Québec
Fonds de la Recherche en Santé du Québec

Registry information

Acronym: GEN3G

Important dates

Study start: 2010
Primary completion: 2025
Study completion: 2025
First posted: Jun 20, 2012
Registry last updated: Oct 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed